AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...
Cautious Optimism: Amgen’s Uplizna Shows Promise but Limited Immediate Impact on Valuation
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.
FiercePharma25d
With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
Uplizna was one of the key drugs acquired from the company’s $27.8 billion acquisition of Horizon Therapeutics, which was completed in October of last year. Amgen Uplizna Myasthenia Gravis ...
Amgen Reports Positive Phase 3 Data For Uplizna In Generalized Myasthenia Gravis
Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...
Amgen stock slides 5% as analysts weigh in on drug study results (update)
Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...
KTLA5d
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA ...